Paclitaxel plus carboplatin, which is a chemotherapy regimen, has relatively large side effects. Generally speaking, for patients, the main side effects are in bone marrow transplantation, which means that hematologic toxicity may cause a decrease in white blood cells, a decrease in neutrophils, and may also cause nausea, vomiting, and other digestive system symptoms. Therefore, before using this option, it is important to weigh the pros and cons of whether the patient’s health condition is suitable for the application. If it is suitable for application, only then will the application of this regimen be considered, and the appropriate dose should be given, and pretreatment should be given before the administration of the drug, such as the administration of antiemetic drugs to prevent the occurrence of nausea and vomiting. Therefore, in clinical application, if paclitaxel plus carboplatin is needed, even if there are certain side effects or adverse reactions, the drug will be given, and the main consideration is the efficacy of the drug, which should be suitable for the patient to control the tumor. Adverse reactions should be given in a timely manner to prevent them, or the appearance of adverse reactions can be intervened to be able to get some effective control. Therefore, as long as the drug is used under the guidance of oncologists and combined with the specific conditions of patients, it is safer to apply it accordingly, and adverse reactions are inevitable, but patients will consider applying this drug only after benefiting from this program.